You are here

Treatment with human pituitary gonadotrophins

Document

Creutzfeldt-Jakob disease - Treatment with human pituitary gonadotrophins Factor

Last reviewed for CCPS 15 May 1998.

Preliminary questions [16284]

16374 there is some evidence that treatment with human pituitary gonadotrophins may be a factor in the development of the condition under consideration.

1169the veteran is a woman.

16297

the veteran has had treatment with human pituitary gonadotrophins at some time.

16298

the veteran had treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease.

16300the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and VEA service for Creutzfeldt-Jakob disease.

16301the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and operational service for the clinical onset of Creutzfeldt-Jakob disease.

or

16302the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and eligible service for the clinical onset of Creutzfeldt-Jakob disease.

Clinical onset and operational service [16301]

24914

the veteran had treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease on operational service.

or

16299

the treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease was for an illness or injury which is identifiable.

16303the identified illness or injury for which treatment with human pituitary gonadotrophins was given is causally related to operational service.

Clinical onset and eligible service [16302]

16299

the treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease was for an illness or injury which is identifiable.

16304the identified illness or injury for which treatment with human pituitary gonadotrophins was given is causally related to eligible service.